CLINICAL_TRIALS
trial_result
· 2023-10-11
Clinical Trial Update: Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 [Phase 2]
Summary
A Phase 2 safety and efficacy study evaluating pyridostigmine in patients with Spinal Muscular Atrophy Type 3 has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Centre Hospitalier Régional de la Citadelle | Conditions: Spinal Muscular Atrophy Type 3 | Phase 2 | Status: COMPLETED